中德临床肿瘤学杂志(英文版)2007，Vol.6Issue(2)：162-169,8.
胰腺癌:新辅助治疗
Pancreatic cancer-Neoadjuvant therapy
R. Krempien 1M. W. Munter 1W. Harms 1J. Debus1
作者信息
- 1. Department of Radiation Oncology, University of Heidelberg, INF 400, 69120 Heidelberg, Germany
- 折叠
摘要
Abstract
In spite of the high mortality in pancreatic cancer, significant progress is being made. This review discusses multimodality therapy for patients with pancreatic cancer. Surgical therapy currently offers the only potential monomodal cure for pancreatic adenocarcinoma. However only 10%-20% of patients present with tumors that are amenable to resection,and even after resection of localized cancers, long term survival is rare. The addition of chemoradiation therapy significantly increases median survival. To achieve long-term success in treating this disease it is therefore increasingly important to identify effective neoadjuvant/adjuvant multimodality therapies. Preoperative chemoradiation for potentially resectable pancreatic cancer has the following advantages:(1) neoadjuvant treatment would eliminate the delay of adjuvant treatment due to postoperative complications; (2) neoadjuvant treatment could avoid unnecessary surgery for patients with metastatic disease evident on restaging after neoadjuvant therapy; (3) downstaging after neoadjuvant therapy may increase the likelihood for negative surgical margins; and (4) neoadjuvant treatment could prevent peritoneal tumor cell implantation and dissemination caused during surgery. This review systematically summarizes the current status, controversies, and prospects of neoadjuvant treatment of pancreatic cancer.关键词
pancreatic cancer/neoadjuvant therapy/advantageKey words
pancreatic cancer/neoadjuvant therapy/advantage分类
临床医学引用本文复制引用
R. Krempien,M. W. Munter,W. Harms,J. Debus..胰腺癌:新辅助治疗[J].中德临床肿瘤学杂志(英文版),2007,6(2):162-169,8.
